NanoPass Is Joining Forces with Pharma Partners in The Fight Against The COVID-19 Pandemic
Zika remains a major public health threat, and its devastating neurological effects on newborns and infants are still being unraveled. More than ever, a vaccine is needed to protect against Zika virus, which is now considered on par with dangerous mosquito-borne viral diseases, like dengue, Japanese encephalitis or yellow fever. IDRI (Infectious Disease Research Institute) and NanoPass Technologies have signed a collaboration agreement to develop and test a new Zika vaccine based on a replicating viral RNA (rvRNA) construct administered intradermally using NanoPass's proprietary MicronJet600® microneedle device.